Table 4.

Associations of serum 1,25(OH)2D levels with infectious composite events, cardiac composite events or all-cause mortality

1,25(OH)2D pg/mlBaseline 1,25(OH)2D as ExposureTime-Dependent 1,25(OH)2D as Exposure
Composite of First Infectious Hospitalization or Infectious Death
HR (95% CI), by QuartileHR (95% CI), by Quartile
Q1Q2Q3Q4Q1Q2Q3Q4
< 2.82.8–6.36.3–14.4>14.4< 2.82.8–6.36.3–14.4>14.4
# of Events118131120130118131120130
Model 11.01.16 (0.88–1.53)0.96 (0.72–1.28)1.24 (0.93–1.65)1.01.29 (0.98–1.68)1.02 (0.77–1.35)1.17 (0.88–1.54)
Model 21.01.09 (0.82–1.45)0.84 (0.62–1.13)1.16 (0.87–1.54)1.01.26 (0.96–1.66)0.97 (0.72–1.29)1.17 (0.88–1.55)
Model 31.01.18 (0.89–1.56)1.00 (0.74–1.36)1.31 (0.96–1.80)1.01.29 (0.98–1.69)1.02 (0.77–1.36)1.17 (0.88–1.56)
Composite of First Cardiac Hospitalization or Cardiac Death
# of Events129127120138129127120138
Model 11.00.81 (0.62–1.08)0.78 (0.58–1.04)0.96 (0.72–1.27)1.01.23 (0.94–1.62)1.00 (0.75–1.32)1.05 (0.79–1.39)
Model 21.00.81 (0.61–1.07)0.77 (0.57–1.03)0.98 (0.74–1.30)1.01.24 (0.95–1.63)1.00 (0.76–1.33)1.08 (0.81–1.43)
Model 31.00.84 (0.64–1.12)0.88 (0.65–1.20)1.14 (0.83–1.58)1.01.25 (0.95–1.64)1.05 (0.79–1.40)1.14 (0.85–1.52)
All-Cause Mortality
# of Events149148132153149148132153
Model 11.00.85 (0.65–1.11)0.80 (0.60–1.07)1.03 (0.79–1.36)1.00.92 (0.71–1.18)0.73 (0.56–0.96)0.92 (0.70–1.20)
Model 21.00.84 (0.63–1.11)0.77 (0.58–1.04)1.02 (0.76–1.35)1.00.90 (0.70–1.17)0.74 (0.56–0.98)0.98 (0.74–1.30)
Model 31.00.87 (0.66–1.14)0.85 (0.63–1.15)1.13 (0.84–1.54)1.00.92 (0.71–1.18)0.73 (0.55–0.96)0.92 (0.70–1.21)
  • Model 1: Adjusted for age, gender, race, diabetic status, history of cardiac disease, years of dialysis, smoking status, urea Kt/V, and dialysis membrane flux assignments, central catheter use, serum calcium, serum phosphorus, serum intact parathyroid hormone, serum 25-hydroxyvitamin D, and serum FGF23.

  • Model 2: Adjusted for covariates in Model 1 plus serum albumin, serum high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-α, and interferon-γ.

  • Model 3: Adjusted for covariates in Model 2 plus vitamin D analog administration.

  • Quartile 1 is the reference group in all models.